DOCSLIB.ORG

Influenza Vaccination Policy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Influenza Vaccination Policy NORTH KANSAS CITY HOSPITAL FLU VACCINATION Purpose To prevent the acquiring and transmission of the Influenza virus. According to the Centers for Disease Control and Prevention (CDC), vaccination is considered the single most important influenza control measure to reduce the chances that you will get the seasonal flu and lessen the chance that you will spread it to others. When more people get vaccinated against the flu, less flu can spread through the community. Audience All employees, medical staff members, allied health personnel, ancillary personnel, contract/agency personnel, residents, medical students and other students, job shadows, vendors with patient contact and volunteers. Policy As a condition of employment and/or affiliation, North Kansas City Hospital requires annual influenza vaccination for individuals that have job duties and/or physical presence inside any North Kansas City Hospital owned and/or leased facilities or properties. North Kansas City Hospital will offer the flu vaccination free of charge. Procedure Step Action 1 The flu vaccine is administered by Employee Health each year when the vaccine becomes available. Notification of vaccine availability will be via hospital email and other notifications. 2 The vaccination start date for each year and the deadline by which individuals are required to have received the vaccination each year (the "Vaccination Deadline") will be set annually at the recommendation of the Infection Control Committee Chairperson. An authorization/consent form is signed prior to the administration of the vaccine. Managers will be notified yearly of the percentage rate of flu vaccine recipients within their departments to share with employees as an educational tool. Facility vaccination rates will be calculated and reported as required using the National Quality Forum (NQF) #0431: Influenza Vaccination Coverage Among Healthcare Personnel. 3 Individuals new to NKCH after March 31 of each year will be notified of the policy and will be expected to comply with the vaccination requirement for the next influenza season. Individuals new to NKCH during the flu season will be expected to comply with the vaccination requirement immediately. 4 1. Individuals may request a medical accommodation to be Medical exempt from the flu vaccine requirement if they have a medical contraindication that is: a) listed in the vaccine manufacturer's Accommo­ prescribing information; orb) listed by the Centers for Disease dations Control and Prevention (CDC). 2. Individuals requesting a medical accommodation must complete a Request for Accommodation form, signed by the individual's personal, treating physician. Request for Accommodation forms signed by an emergency medicine physician or a hospitalist will not be accepted unless documentation proves treatment by that physician. Request for Accommodation forms signed by chiropractors will not be accepted. Request for Accommodation forms must be completed and turned into the Employee Health Department by the date that is fourteen (14) days prior to the Page 1 of4 NORTH KANSAS CITY HOSPITAL Procedure Step Action Vaccination Deadline. 3. If additional information regarding a medical accommodation request is necessary, the individual will be notified and will have fourteen (14) days from the date of the notification to submit to the Employee Health Department any additional information that the individual wishes to be considered in the evaluation of the request. An individual may be required to sign a release of information authorization form to be sent by the Employee Health Department to the individual's physician, requesting records and/or requesting the physician to contact the Infection Control Committee Chairperson to discuss the request for an accommodation. If the individual's physician does not provide the requested records or contact the Infection Control Committee Chairperson prior to the Vaccination Deadline, the request for accommodation may be denied. 4. All requests for accommodation due to medical contraindications will be subject to approval by the Infection Control Committee Chairperson. 5. If a request for an accommodation is not received by the Employee Health Department by the date that is fourteen (14) days prior to the Vaccination Deadline it will not be accepted and the individual will be expected to complete the vaccination before the Vaccination Deadline or face disciplinary action. (See policy, Mandatory Educational/Safety Requirements). 6. If the request for accommodation is denied, the individual will be expected to complete the vaccination before the Vaccination Deadline or face disciplinary action. (See policy, Mandatory Educational/Safety Requirements). 7. Individuals approved for accommodation for medical reasons will be required to wear a mask, during flu season, while inside any owned and/or leased facilities or properties in any patient care areas. If the individual does not work in a patient care area but is exhibiting symptoms that may be related to the flu, the individual will be required to wear a mask until he or she is symptom free for at least twenty four (24) hours. Individuals approved for accommodation must obtain a new identification badge from the Human Resources Department with a border color variation that will signify that the mask requirement applies to that individual. The mask requirement is also mandatory and will be enforced by the department manager. 5 1. Individuals may request a religious accommodation to be Religious exempt from the flu vaccine requirement if they have a sincerely held, bona fide religious belief that does not permit the individual Accommo­ to receive the influenza vaccine. Requests for accommodation dations will not be granted based on secular philosophical, political, scientific or sociological objections to the influenza vaccine. 2. Individuals requesting a religious accommodation must Page 2 of4 NORTH KANSAS CITY HOSPITAL Procedure Step Action complete a Request for Accommodation form, and must submit documentation from the individual's religious leader (or other individual who can attest to the individual's religious belief) outlining the specific and current religious objection to the influenza vaccine. Request for Accommodation forms must be completed and turned into the Employee Health Department by the date that is fourteen (14) days prior to the Vaccination Deadline. 3. If additional information regarding a religious accommodation request is necessary, the individual will be notified and will have fourteen (14) days from the date of the notification to submit to the Employee Health Department any additional information that the individual wishes to be considered in the evaluation of the request. Additionally, individuals may be required to discuss, or their identified religious leader may be required to discuss, the request for accommodation with a NKCH Chaplain or other designated faith-based support service. If the individual or the individual's religious leader does not discuss the matter with the NKCH Chaplain or designee prior to the Vaccination Deadline, the request for accommodation may be denied. 4. All requests for accommodation due to religious reasons will be subject to approval by a committee consisting of the Infection Control Committee Chairperson, a NKCH Chaplain, a representative from the Human Resources Department, and a representative from the Employee Health Department. 5. If a request for an accommodation is not received by the Employee Health Department by the date that is fourteen (14) days prior to the Vaccination Deadline it will not be accepted and the individual will be expected to complete the vaccination before the Vaccination Deadline or face disciplinary action. (See policy, Mandatory Educational/Safety Requirements). 6. If the request for accommodation is denied, the individual will be expected to complete the vaccination before the Vaccination Deadline or face disciplinary action. (See policy, Mandatory Educational/Safety Requirements). 7. Individuals approved for accommodation for religious reasons will be required to wear a mask, during flu season, while inside any owned and/or leased facilities or properties in any patient care areas. If the individual does not work in a patient care area but is exhibiting symptoms that may be related to the flu , the individual will be required to wear a mask until he or she is symptom free for at least twenty four (24) hours. Individuals approved for accommodation must obtain a new identification badge from the Human Resources Department with a border color variation that will signify that the mask requirement applies to that individual. The mask requirement is also mandatory and will be enforced by the department manager. Page 3 of4 NORTH KANSAS CITY HOSPITAL Procedure Step Action Received at 6 Individuals who receive the influenza vaccination other than at NKCH other facilities will be required to submit proof of vaccination documentation to the Employee Health Department by the Vaccination Deadline. 7 Employees who do not comply with this policy by the Vaccination Deadline will be subject to disciplinary action up to and including termination. (See policy, Mandatory Educational/Safety Requirements). Non-employees who do not comply with this policy will be separated from affiliation with NKCH or the non-compliance will be referred to the appropriate medical staff committee for action. References: MMWR, Immunization of Healthcare Personnel - Recommendations of the Advisory Committee on Immunization Practices (ACIP), November 25, 2011 , Volume 60, No. 7. Association of Professionals in Infection Control and Epidemiology (APIC) Position Paper: Influenza Immunization of Healthcare Personnel, 2008. Association of Professionals in Infection Control and Epidemiology (APIC) Position Paper: Influenza Vaccination Should Be A Condition Of Employment for Healthcare Personnel Unless Medically Contraindicated, 2011 . Page 4 of4 .
Load more

Recommended publications
  • Gavi's Vaccine Investment Strategy
    Gavi’s Vaccine Investment Strategy Deepali Patel THIRD WHO CONSULTATION ON GLOBAL ACTION PLAN FOR INFLUENZA VACCINES (GAP III) Geneva, Switzerland, 15-16 November 2016 www.gavi.org Vaccine Investment Strategy (VIS) Evidence-based approach to identifying new vaccine priorities for Gavi support Strategic investment Conducted every 5 years decision-making (rather than first-come- first-serve) Transparent methodology Consultations and Predictability of Gavi independent expert advice programmes for long- term planning by Analytical review of governments, industry evidence and modelling and donors 2 VIS is aligned with Gavi’s strategic cycle and replenishment 2011-2015 Strategic 2016-2020 Strategic 2021-2025 period period 2008 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 RTS,S pilot funding decision VIS #1 VIS #2 VIS #3 MenA, YF mass campaigns, JE, HPV Cholera stockpile, Mid 2017 : vaccine ‘long list’ Rubella, Rabies/cholera studies, Oct 2017 : methodology Typhoid Malaria – deferred Jun 2018 : vaccine shortlist conjugate Dec 2018 : investment decisions 3 VIS process Develop Collect data Develop in-depth methodology and Apply decision investment decision framework for cases for framework with comparative shortlisted evaluation analysis vaccines criteria Phase I Narrow long list Phase II Recommend for Identify long list to higher priority Gavi Board of vaccines vaccines approval of selected vaccines Stakeholder consultations and independent expert review 4 Evaluation criteria (VIS #2 – 2013) Additional Health Implementation
    [Show full text]
  • Package Insert
    HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------------- CONTRAINDICATIONS ------------------------------------- These highlights do not include all the information needed to use ® • History of severe allergic reactions (e.g., anaphylaxis) to egg proteins, or any FLUVIRIN (Influenza Virus Vaccine) safely and effectively. See full ® ® component of FLUVIRIN , or life-threatening reactions to previous influenza prescribing information for FLUVIRIN . vaccinations. (4.1, 11) FLUVIRIN® (Influenza Virus Vaccine) Suspension for Intramuscular Injection ---------------------- WARNINGS AND PRECAUTIONS ------------------------------ 2017-2018 Formula • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior Initial US Approval: 1988 influenza vaccine, the decision to give FLUVIRIN® should be based on -------------------------- INDICATIONS AND USAGE ---------------------------------- careful consideration of the potential benefits and risks. (5.1) ® • FLUVIRIN is an inactivated influenza virus vaccine indicated for active • Immunocompromised persons may have a reduced immune response to immunization of persons 4 years of age and older against influenza disease FLUVIRIN®. (5.2) caused by influenza virus subtypes A and type B contained in the vaccine (1). • The tip caps of the FLUVIRIN® prefilled syringes may contain natural rubber • FLUVIRIN® is not indicated for children less than 4 years of age because latex which may cause allergic reactions in latex sensitive individuals. there is evidence of diminished immune response
    [Show full text]
  • Global Challenges in Seasonal Influenza Vaccine Supply, Use, and Policy
    Intersect, Vol 12, No. 1 (2018) Global Challenges in Seasonal Influenza Vaccine Supply, Use, and Policy Kaitlin Schroeder Stanford University Abstract Seasonal influenza outbreaks occur on every continent, infecting millions and killing around 500,000 patients each year. The 2018 influenza season has been a vicious one—the H3N2 strain is a fast-mutating, aggressive form of the virus, and we have had difficulty immunizing against it. Decreasing the devastation of seasonal influenza starts with smart vaccine systems: a greater supply of doses distributed to the right people. In this review, we evaluate the global threat of seasonal influenza and explore the availability of vaccines as an essential prevention mechanism. We first identify key stakeholders in global influenza policy, vaccine supply, and regional public health governance. Next, we define the extent of the need for vaccines by examining surveillance systems and assessing the current disease burden of seasonal influenza. We examine current challenges in vaccine availability and allocation, and their respective impacts on health outcomes. Finally, we discuss policy implications of supply and allocation studies; we particularly note the promising outlook of communication programs, the advantages of optimized dose distribution, and the need to concentrate on infrastructure in low-income countries. Schroeder, Global Influenza Vaccine Challenges Introduction “Vaccines are miracles.” Professor Pedro Alonso of the Institute of Global Health, Barcelona explains that just a few dollars spent on immunization can protect an individual from severe disease and disability, making vaccines “one of the best investments in health” (Robert, n.d.). Among the recognized vaccine-preventable diseases (VPDs) is seasonal influenza, an acute viral infection that affects millions of people worldwide every year.
    [Show full text]
  • Recommended Adult Immunization Schedule
    Recommended Adult Immunization Schedule UNITED STATES for ages 19 years or older 2021 Recommended by the Advisory Committee on Immunization Practices How to use the adult immunization schedule (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Determine recommended Assess need for additional Review vaccine types, Control and Prevention (www.cdc.gov), American College of Physicians 1 vaccinations by age 2 recommended vaccinations 3 frequencies, and intervals (www.acponline.org), American Academy of Family Physicians (www.aafp. (Table 1) by medical condition and and considerations for org), American College of Obstetricians and Gynecologists (www.acog.org), other indications (Table 2) special situations (Notes) American College of Nurse-Midwives (www.midwife.org), and American Academy of Physician Assistants (www.aapa.org). Vaccines in the Adult Immunization Schedule* Report y Vaccines Abbreviations Trade names Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department Haemophilus influenzae type b vaccine Hib ActHIB® y Clinically significant postvaccination reactions to the Vaccine Adverse Event Hiberix® Reporting System at www.vaers.hhs.gov or 800-822-7967 PedvaxHIB® Hepatitis A vaccine HepA Havrix® Injury claims Vaqta® All vaccines included in the adult immunization schedule except pneumococcal 23-valent polysaccharide (PPSV23) and zoster (RZV) vaccines are covered by the Hepatitis A and hepatitis B vaccine HepA-HepB Twinrix® Vaccine Injury Compensation Program. Information on how to file a vaccine injury Hepatitis B vaccine HepB Engerix-B® claim is available at www.hrsa.gov/vaccinecompensation. Recombivax HB® Heplisav-B® Questions or comments Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Human papillomavirus vaccine HPV Gardasil 9® Spanish, 8 a.m.–8 p.m.
    [Show full text]
  • UNICEF Deep-Dive 2020, Vaccine Industry Consultation UNICEF’S Tentative Vaccine Tender Calendar for the Upcoming Period INFLUENZA Deep-Dive Agenda
    UNICEF Deep-dive 2020, Vaccine Industry Consultation UNICEF’s Tentative Vaccine Tender Calendar for the upcoming period INFLUENZA Deep-dive Agenda • Background and challenges • Feedback from the industry • Gavi learning agenda for seasonal influenza​ • Tender timelines • Key takeaways 4 Background & Challenges • Immunization programmes, vaccines, and auxiliary supplies for seasonal influenza are primarily funded through a country’s own health budget. • Due to limited funding, seasonal influenza programmes are often not implemented in LICs and MICs. • Historically, UNICEF has procured limited quantities of influenza vaccine on behalf of countries. • UNICEF often receives requests for supply of seasonal influenza vaccine late and after suppliers have determined the production volume for the global market. • Due to COVID-19, the demand for seasonal influenza vaccines through UNICEF has increased during 2020, and realized late which let to constrained availability for countries procuring through UNICEF. UNICEF plans to tender earlier to counter this risk. Feedback from the industry What should UNICEF do differently to incentivize your participation in the future tenders for seasonal influenza vaccines? Feedback from the industry Measures taken by UNICEF • Tender one year in advance to block the • Advance tender timelines​ doses for UNICEF. • Stakeholders reminded of: • Multi-year tender and LTA​ o the short window for production planning and supply​ • UNICEF take risks and commit to pay for o importance of timely and accurate the doses even they are not materialised forecasting​ into orders. • Published a Supply Note on Seasonal Influenza Vaccines in English & French. • Working with countries to improve longer- term forecast accuracy. 6 Gavi learning agenda for seasonal influenza • Background: only 8% of Gavi eligible • Duration of the project: 2021 – 2022 countries have seasonal influenza immunization programmes, and most • Targeted countries: Cote d’Ivoire, Kenya & countries in the African region do not have Uganda national influenza immunization policies.
    [Show full text]
  • Using Influenza Vaccination Location Data from the 2018 Behavioral Risk
    International Journal of Environmental Research and Public Health Article Using Influenza Vaccination Location Data from the 2018 Behavioral Risk Factor Surveillance System (BRFSS) to Expand COVID-19 Vaccination Coverage Victoria Fonzi 1, Kiran Thapa 2, Kishor Luitel 3, Heather Padilla 4, Curt Harris 5, M. Mahmud Khan 1, Glen Nowak 6 and Janani Rajbhandari-Thapa 1,* 1 Department of Health Policy and Management, College of Public Health, University of Georgia, Athens, GA 30602, USA; [email protected] (V.F.); [email protected] (M.M.K.) 2 Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens, GA 30602, USA; [email protected] 3 School of Agriculture, Middle Tennessee State University, Murfreesboro, TN 37132, USA; [email protected] 4 Department of Health Promotion & Behavior, College of Public Health, University of Georgia, Athens, GA 30602, USA; [email protected] 5 Institute for Disaster Management, College of Public Health, University of Georgia, Athens, GA 30602, USA; [email protected] 6 Grady College Center for Health and Risk Communication, Grady College of Journalism and Mass Communication, University of Georgia, Athens, GA 30602, USA; [email protected] * Correspondence: [email protected] Citation: Fonzi, V.; Thapa, K.; Luitel, K.; Padilla, H.; Harris, C.; Khan, M.M.; Abstract: Effective COVID-19 vaccine distribution requires prioritizing locations that are accessible Nowak, G.; Rajbhandari-Thapa, J. to high-risk target populations. However, little is known about the vaccination location preferences Using Influenza Vaccination Location Data from the 2018 Behavioral Risk of individuals with underlying chronic conditions. Using data from the 2018 Behavioral Risk Factor Factor Surveillance System (BRFSS) to Surveillance System (BRFSS), we grouped 162,744 respondents into high-risk and low-risk groups Expand COVID-19 Vaccination for COVID-19 and analyzed the odds of previous influenza vaccination at doctor’s offices, health Coverage.
    [Show full text]
  • Vaccine Names and Abbreviations Vaccine Names and Abbreviations Many Vaccines Are Documented in an Abbreviation and Not by Their Full Name
    Vaccine Names and Abbreviations Vaccine Names and Abbreviations Many vaccines are documented in an abbreviation and not by their full name. This page is designed to assist you in interpreting both old and new immunization records such as the yellow California Immunization Record, the International Certificate of Vaccination (Military issued shot record) or the Mexican Immunization Card described in the shaded sections. Vaccine Abbreviation/Name What it Means Polio Oral Polio oral poliovirus vaccine (no longer used in U.S.) OPV Orimune Trivalent Polio TOPV Sabin oral poliovirus Inactivated Polio injectable poliovirus vaccine eIPV IPOL IPV Pentacel combination vaccine: DTaP/Hib/IPV Pediarix combination vaccine: diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b and inactivated poliovirus (DTaP/IPV/Hep B) DTP or DPT combination vaccine: diphtheria, tetanus, pertussis (no longer DTP Tri-Immunol available in U.S.) (Diphtheria, Tetanus, Pertussis) Triple combination vaccine: difteria, tétano, tos ferina (diphtheria, tetanus pertussis) DT combination vaccine: diphtheria and tetanus vaccine (infant vaccine without pertussis component used through age 6) DTaP combination vaccine: diphtheria, tetanus and acellular pertussis DTaP/Tdap Acel-Imune Certiva (Diphtheria, Tetanus, acellular Daptacel Pertussis) Infanrix Tripedia Tdap combination vaccine: tetanus, diphtheria, acellular pertussis Adacel (improved booster vaccine containing pertussis for adolescents Boostrix and adults) DTP-Hib combination vaccine: diphtheria, tetanus,
    [Show full text]
  • Pfizer-Biontech COVID VACCINE CONSENT 2021 Information About the Person Receiving the Vaccine (Please Print)
    Pfizer-BioNTech COVID VACCINE CONSENT 2021 Information about the person receiving the vaccine (Please Print) Last Name: First Name: Date of Birth: Mailing Address: Apt/Suite: City: State: Zip: County: Phone Number: Sex: □ Male □ Female Gender Identity: □ Male □ Female □ MTF □ FTM □ Nonbinary □ Questioning Race: Hispanic Origin: □ Asian □ Black □ Non-Hispanic □ American Indian/Alaskan Native □ White □ Hispanic □ Unknown □ Hawaiian/Pacific Islander □ Other: _______________ Have you previously received a COVID-19 vaccine? * □ Yes □ No □ I don’t know Have you had a severe allergic reaction (e.g., anaphylaxis) after receiving COVID-19 vaccine or any medication given via injection or polyethylene glycol (MiraLAX)? □ Yes □ No □ I don’t know Are you immunocompromised (have a weakened immune system such as cancer, leukemia, HIV/AIDS, or any other immune system problem) or are you taking medication that affects your immune system? □ Yes □ No □ I don’t know In the last 10 days, have you had a fever or any ill symptoms or been exposed to COVID? □ Yes □ No □ I don’t know Have you had any vaccines in the last 14 days? □ Yes □ No □ I don’t know Have you received COVID antibody therapy in the last 90 days? □ Yes □ No □ I don’t know Could you become pregnant in the next several weeks or are you breastfeeding? * If so, you must speak with your OB prior to making the appointment. □ Yes □ No □ I don’t know Consent for COVID-19 VACCINATION You must sign this to be VACCINATED. By signing this form, I give permission for a COVID-19 VACCINATION to be administered and a record of the VACCINE and results be entered into a database for use to monitor control of the disease.
    [Show full text]
  • Product Information for Pandemrix H1N1 Pandemic Influenza Vaccine
    Attachment 1: Product information for Pandemrix H1N1 pandemic influenza vaccine. Influenza virus haemagglutinin (A/California/7/2009(H1N1)v-like strain). GlaxoSmithKline Australia Pty Ltd. PM-2010- 02995-3-2 Final 12 February 2013. This Product Information was approved at the time this AusPAR was published. PANDEMRIX™ H1N1 PRODUCT INFORMATION Pandemic influenza vaccine (split virion, inactivated, AS03 adjuvanted) NAME OF THE MEDICINE PANDEMRIX H1N1, emulsion and suspension for emulsion for injection. Pandemic influenza vaccine (split virion, inactivated, AS03 adjuvanted). DESCRIPTION Each 0.5mL vaccine dose contains 3.75 micrograms1 of antigen2 of A/California/7/2009 (H1N1)v- like strain and is adjuvanted with AS033. 1haemagglutinin 2propagated in eggs 3The GlaxoSmithKline proprietary AS03 adjuvant system is composed of squalene (10.68 milligrams), DL-α-tocopherol (11.86 milligrams) and polysorbate 80 (4.85 milligrams) This vaccine complies with the World Health Organisation (WHO) recommendation for the pandemic. Each 0.5mL vaccine dose also contains the excipients Polysorbate 80, Octoxinol 10, Thiomersal, Sodium Chloride, Disodium hydrogen phosphate, Potassium dihydrogen phosphate, Potassium Chloride and Magnesium chloride. The vaccine may also contain the following residues: egg residues including ovalbumin, gentamicin sulfate, formaldehyde, sucrose and sodium deoxycholate. CLINICAL TRIALS This section describes the clinical experience with PANDEMRIX H1N1 after a single dose in healthy adults aged 18 years and older and the mock-up vaccines (Pandemrix H5N1) following a two-dose administration. Mock-up vaccines contain influenza antigens that are different from those in the currently circulating influenza viruses. These antigens can be considered as “novel” antigens and simulate a situation where the target population for vaccination is immunologically naïve.
    [Show full text]
  • Safety and Immunogenicity of a Plant-Produced
    Viruses 2012, 4, 3227-3244; doi:10.3390/v4113227 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Article Safety and Immunogenicity of a Plant-Produced Recombinant Hemagglutinin-Based Influenza Vaccine (HAI-05) Derived from A/Indonesia/05/2005 (H5N1) Influenza Virus: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study in Healthy Adults Jessica A. Chichester, R. Mark Jones, Brian J. Green, Mark Stow, Fudu Miao, George Moonsammy, Stephen J. Streatfield and Vidadi Yusibov * Fraunhofer USA, Center for Molecular Biotechnology, Newark, DE 19711, USA; E-Mails: [email protected] (J.A.C.); [email protected] (R.M.J.); [email protected] (B.J.G.); [email protected] (M.S.); [email protected] (F.M.); [email protected] (G.M.); [email protected] (S.J.S.); [email protected] (V.Y.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-302-369-3766; Fax: +1-302-369-8955. Received: 25 October 2012; in revised form: 15 November 2012 / Accepted: 16 November 2012 / Published: 19 November 2012 Abstract: Recently, we have reported [1,2] on a subunit influenza vaccine candidate based on the recombinant hemagglutinin protein from the A/Indonesia/05/2005 (H5N1) strain of influenza virus, produced it using ‘launch vector’-based transient expression technology in Nicotiana benthamiana, and demonstrated its immunogenicity in pre-clinical studies. Here, we present the results of a first-in-human, Phase 1 randomized, double-blind, placebo-controlled study designed to investigate safety, reactogenicity and immunogenicity of three escalating dose levels of this vaccine, HAI-05, (15, 45 and 90 µg) adjuvanted with Alhydrogel® (0.75 mg aluminum per dose) and the 90 µg dose level without Alhydrogel®.
    [Show full text]
  • HPV and Adolescent Vaccine Toolkit: Clinician Guide Contents
    HPV and Adolescent Vaccine Toolkit: Clinician Guide CONTENTS I. 2018 IMMUNIZATION SCHEDULES & SCREENING RESOURCES Recommended & Catch-up Immunization Schedule (Birth-18 Years) Lists the ages or age range each vaccine is recommended. Schedules are updated annually. Please visit https://www.cdc.gov/vaccines/schedules/ for the most up-to-date schedules. Clinician FAQ: CDC Recommendations for HPV Vaccine 2-Dose Schedules Helps explain the new HPV vaccine recommendation for adolescents (2 doses recommended for adolescents starting the series before their 15th birthday; 3 doses recommended for adolescents starting the series after their 15th birthday) and provides tips for talking to parents about the change. HPV 2-Dose Decision Tree Follow the decision tree chart to determine whether your patient needs two or three doses of HPV vaccine. II. ADDRESSING VACCINE HESITANCY Talking to Parents About the HPV Vaccine A collection of questions parents may have surrounding the HPV vaccine and responses healthcare providers can use to address the concerns. Let’s Talk Vaccines: A Guide to Conversations About Immunizations Parents ask tough questions! Use this resource from Northwest Vax to provide a strong recommendation using the Ask. Acknowledge. Advise model. III. BEST PRACTICES AND STRATEGIES FOR IMPROVING IMMUNIZATION COVERAGE RATES Strategies for Improving Adolescent Immunization Coverage Rates Use the strategies in this AAP resource to help your practice improve adolescent immunization coverage rates among your patients. Documenting Parental Refusal to Have Their Children Vaccinated Provides tips from the AAP on ways to communicate with and educate parents who refuse immunizations. Includes a template for use by health care providers to document refusals.
    [Show full text]
  • Recommended Composition of Influenza Virus Vaccines for Use in the 2021- 2022 Northern Hemisphere Influenza Season
    Recommended composition of influenza virus vaccines for use in the 2021- 2022 northern hemisphere influenza season February 2021 WHO convenes technical consultations1 in February and September each year to recommend viruses for inclusion in influenza vaccines 2 for the northern and southern hemisphere influenza seasons, respectively. This recommendation relates to the influenza vaccines for use in the northern hemisphere 2021-2022 influenza season. A recommendation will be made in September 2021 relating to vaccines that will be used for the southern hemisphere 2022 influenza season. For countries in tropical and subtropical regions, WHO recommendations for influenza vaccine composition (northern hemisphere or southern hemisphere) are available on the WHO Global Influenza Programme website3. Seasonal influenza activity Public health and laboratory responses to the COVID-19 pandemic, caused by the coronavirus SARS- CoV-2, initially led to reduced influenza surveillance and/or reporting activities in many countries, which have been improving. Additionally, COVID-19 mitigation strategies including restrictions on travel, use of respiratory protection, and social-distancing measures in most countries have contributed to decreased influenza activity. Overall, record-low levels of influenza detections were reported and fewer viruses were available for characterization during the September 2020 to January 2021 time- period than in previous years. Between September 2020 and January 2021, influenza A(H1N1)pdm09, A(H3N2) and influenza B viruses circulated in very low numbers and the relative proportions of the viruses circulating varied among reporting countries. Globally, since September 2020, influenza activity was mostly reported from countries in the tropics and subtropics and some countries in the temperate zone of the northern hemisphere.
    [Show full text]